The AIDS Healthcare Foundation (AHF) has written letters to US state Medicaid directors suggesting they block Gilead Sciences’ Sovaldi from inclusion in their drug formularies, in hopes of securing a more reasonable price. The $1000 per pill price tag for this drug represents a 279,000% retail markup- leading patients, payers and providers asking; when is enough, enough? Read AHF’s letter to state Medicaid directors here. (Source: AHF, 1/29/14).
You are here: / / Market Access Didn’t See This Coming….